The AHSN Network is a key member of the AAC, the umbrella body across the UK health innovation ecosystem, providing more joined up support for innovators and setting the strategy for innovation in the health system. Find out more.

The AAC supports innovation at all stages across the development pipeline: from research and horizon scanning for innovations that address the population’s needs, to support for adoption and spread of proven innovations.

Download the AAC flyer to find out more.

Rapid Uptake Products

The government is providing £2 million to give more patients access to proven innovations through the Accelerated Access Collaborative (AAC).

Seven innovative technology areas were identified by the AAC that improve patients’ lives but are not currently available to everyone who could benefit. This first batch of ‘rapid uptake’ products was selected by leaders in the health and care system, and includes a range of treatments for conditions such as cancer, heart disease and multiple sclerosis.

Supporting the ‘rapid uptake’ products will not only help 500,000 patients to access new treatments, they will also provide cost savings to the NHS of £30 million, while helping to reinforce the UK’s position as a global leader in health innovation.

The products will be spread through the AHSN Network’s Innovation Exchange, which matches solutions to the needs of their local health and care systems.

The rapid uptake products are:

  • HeartFlow analysis creates a 3D model of the coronary arteries to help clinicians to rapidly diagnose patients with suspected coronary artery disease from coronary CT angiography
  • Urolift is a minimally invasive procedure for treating lower urinary tract symptoms of benign prostatic hyperplasia
  • Placental growth factor (PIGF) based tests help predict the risk of pre-eclampsia quickly so that pregnant women receive the most appropriate care
  • High sensitivity troponin tests are used in an early rule out protocol for patients with suspected myocardial infarction
  • Quantitative faecal immunochemical tests (FIT) support patient risk assessment in suspected colorectal cancer
  • Cladribine is an oral treatment given as two treatment courses, one year apart, for treating highly active relapsing-remitting multiple sclerosis in adults
  • PCSK9 inhibitors for treatment of very high cholesterol are used together with a statin-type cholesterol-lowering medicine, or in those who are unable to take or tolerate a statin.

Latest News on the AAC – Pathway Transformation Fund

Funding announced by government in July 2017 is available through the new Accelerated Access Collaborative Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday practices. Delivered with the support of the Academic Health Science Networks (AHSNs) the PTF seeks to improve equality of access to these products.

The PTF can help providers overcome practical obstacles to deploying these products, such as: training staff on how to use new equipment; pathway redesign and/or business support expertise; providing specialist nurses/clinical staff needed to implement a new part of the procedure; or covering double running costs.

Phase Two

After the success of phase one we are pleased to open Phase 2 applications.  This will focus on five of the AAC rapid uptake products: UroLift, placental growth factor-based testing, high-sensitivity troponin testing in an under 3-hour protocol, HeartFlow and PCSK9 inhibitors.

Phase 2 will close midnight on 31 October 2019.  We strongly encourage any Providers wishing to adopt any of these five rapid uptake products to apply.

To request an application form please contact your local AHSN in the first instance to discuss with the relevant AHSN lead for each product.  If you are unsure of your local AHSN please email for clarification

Phase One

The first phase supported three of the AAC rapid uptake products (UroLift, placental growth factor-based testing and high-sensitivity troponin testing in an under 3-hour protocol). 29 applications were received and over £370,000 is being made immediately available across the 16 projects that have been approved. This funding will support in areas such as:

  • Supporting quality improvement programmes.
  • Creating learning sets and delivering coaching to address change management challenges.
  • Funding clinical champions to act as systems leaders to embed the rapid uptake product and associated processes across professional groups.
  • Support to set-up costs such as training and accreditation of staff.

For further enquiries please contact